Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Felip E, Altorki N, Zhou C, et al. Lancet 2021 Oct 9;398(10308):1344-1357.

VIEW

Atezolizumab for first-line treatment of pd-l1-selected patients with NSCLC
Herbst RS, Giaccone G, de Marinis F, et al. N Engl J Med 2020 Oct 1;383(14):1328-1339.

VIEW

Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC
Socinski MA, Jotte RM, Cappuzzo F, et al. N Engl J Med 2018;378:2288- 2301.

VIEW

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
West H, McCleod M, Hussein M, et al. Lancet Oncol 2019 Jul;20(7):924-937.

VIEW

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Rittmeyer A, Barlesi F, Waterkamp D, et al. Lancet 2017;389:255-265.

VIEW

First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn L, Mansfield A, Szczesna A, et al. N Engl J Med 2018 Dec 6;379(23):2220-2229.

VIEW

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn RS, Qin S, Ikeda M, et al. N Engl J Med 2020 May 14;382(20):1894-1905.

VIEW

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Gutzmer R, Stroyakovskiy D, Gogas H, et al. Lancet 2020;395:1835-1844.

VIEW

Naqash A, O'Sullivan Coyne G, Moore N, et al. Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

Presented at the American Society of Clinical Oncology in Virtual; June 4-8, 2022. ASCO Poster #11519. https://www.asco.org/

This poster has not been peer-reviewed. Please click here for full disclosures of potential conflicts of interest provided by the authors.

VIEW

November 9-13, 2022
Onsite/virtual

November 4-8, 2022
Onsite/virtual

October 23-26, 2022
Onsite/virtual

September 9-13, 2022
Onsite

August 6-9, 2022
Onsite

June 29 - July 2, 2022
Onsite

June 3-7, 2022
Onsite/virtual

May 14-17, 2022
Onsite/virtual

May 5-7, 2022
Onsite

May 3-5, 2022
Onsite/virtual

April 8-13, 2022
Onsite

March 30 - April 3, 2022
Onsite

March 30 - April 2, 2022
Onsite/virtual

February 17-19, 2022
Onsite/virtual

February 17-19, 2022
Onsite/virtual

January 20-22, 2022
Onsite/virtual

December 11-14, 2021
Onsite/virtual

December 7-10, 2021
Onsite/virtual

November 12-15, 2021
Virtual

October 28-31, 2021
Virtual

October 24-27, 2021
Virtual

September 16-21, 2021
Virtual

September 11-14, 2021
Virtual

September 2-5, 2021
Virtual

August 13-15, 2021
Virtual

June 23-26, 2021
Virtual

June 4-8, 2021
Virtual

May 5-8, 2021
Virtual

April 10-15, 2021
Virtual

March 24-27, 2021
Virtual

March 19-25, 2021
Virtual

February 11-13, 2021
Virtual

February 4-6, 2021
Onsite

January 15-17, 2021
Virtual

December 8-12, 2020
Onsite

December 5-8, 2020
Onsite